<DOC>
	<DOCNO>NCT00128102</DOCNO>
	<brief_summary>This study determine safety , tolerability , anti-tumor effectiveness oral investigational drug , suberoylanilide hydroxamic acid , treatment advance malignant pleural mesothelioma .</brief_summary>
	<brief_title>Suberoylanilide Hydroxamic Acid ( Vorinostat , MK-0683 ) Versus Placebo Advanced Malignant Pleural Mesothelioma ( 0683-014 AM5 , EXT1 )</brief_title>
	<detailed_description>Treatment Extension Phase : Participants study eligible enroll open-label treatment extension phase : ) originally randomize vorinostat arm experience disease progression ; b ) randomize placebo arm meet `` Extension Phase Inclusion Criteria Participants Placebo Arm '' ; c ) originally randomize vorinostat arm discontinue study therapy reason progression investigator believe participant 's best interest resume vorinostat treatment .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Inclusion Criteria : Participant must 18 year old confirm diagnosis malignant pleural mesothelioma In country pemetrexed approved mesothelioma treatment , participant 's disease progress relapsed follow treatment least one prior chemotherapy regimen pemetrexed either cisplatin carboplatin OR In country pemetrexed approve mesothelioma , participant 's disease progress relapsed follow treatment least one prior chemotherapy regimen OR Pemetrexed prefer therapy participant participant 's disease progress relapsed follow treatment least one prior chemotherapy regimen Participants must receive 2 prior systemic therapy regimens Participant Karnofsky performance scale status ≥70 Participant must adequate bone marrow , liver , kidney function adequate coagulation ( per prespecified laboratory value ) Extension Phase Participants receive treatment vorinostat experience progression mesothelioma Participants randomize placebo arm : 1 ) Karnofsky performance scale status ≥70 ; 2 ) adequate bone marrow , liver , kidney function adequate coagulation ( per prespecified laboratory value ) Participants assign vorinostat discontinue study therapy reason progression mesothelioma , investigator opinion potential benefit outweigh potential risk associate use vorinostat Exclusion Criteria : Participant treat Histone deacetylase [ HDAC ] inhibitor Participant active infection receive treatment intravenous antibiotic , antiviral , antifungal medication within 2 week start study drug . Participants `` currently active '' second malignancy . A malignancy consider `` currently active '' participant complete therapy second malignancy disease free prior malignancy &gt; 5 year Participant uncontrolled brain metastasis Participant know human immunodeficiency virus ( HIV ) infection HIVrelated malignancy Participant pregnant breast feeding Participant history gastrointestinal surgery procedure might interfere absorption swallow study drug Participants take part predose spot postfirst dose 24hour urine collection must exclude medication contain acetominophen paracetamol one week prior start vorinostat therapy entire period urine collection Participants take part predose spot postfirst dose 24hour urine collection may use hemodialysis peritoneal dialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Advanced malignant pleural mesothelioma</keyword>
</DOC>